To verify a hormonal acne claim in 2026, check it against three things: the FDA-approved label for the drug, the 2024 American Academy of Dermatology (AAD) acne guideline, and the actual trial data behind any "clears skin" number. Most bad claims fail at the first step, because the single most-promoted hormonal acne drug in the US — spironolactone — has no FDA approval for acne at all.
Hormonal acne is not an FDA regulatory category. It is a clinical description of acne that tracks with androgens, the hormones that drive oil production, and it usually appears on the jawline, chin and lower face, often flaring around the menstrual cycle. Knowing that the phrase carries no regulatory meaning is the fastest way to spot a page that is selling rather than explaining.
Medical information disclaimer: This article is for general educational purposes only and does not provide medical advice, diagnosis, or treatment. Always consult a physician or other qualified health professional about symptoms, medications, tests, or treatment decisions.
Official resources:
- Read the original report from NIH — Use this primary source to review the complete report.
- Read the original report from FDA — Use this primary source to review the complete report.
Table of Contents
- Start with the label: what the FDA has and has not approved
- Read the guideline's confidence level, not just its recommendation
- The bloodwork question, and how to date a page
- What the strongest trial actually showed — and why testimonials fail
- Should you get a hormone panel? The specialties disagree
- Red flags you can check yourself in two minutes
- Frequently Asked Questions
Start with the label: what the FDA has and has not approved
Spironolactone is a diuretic and anti-androgen. According to FDA drug labeling summarized in the Drugs.com spironolactone monograph, it is labeled for heart failure, high blood pressure, edema and primary hyperaldosteronism — not acne. Every acne use is off-label, which is legal and common, but it means there is no FDA-approved acne dose. Any page advertising an "FDA-approved hormonal acne pill" is wrong on its face.
The one topical drug that blocks androgen receptors in the skin is clascoterone 1% cream, sold as Winlevi. The FDA review for new drug application 213433 shows approval in August 2020 for acne vulgaris in patients aged 12 and up, in both sexes. Note what the label says and does not say: it is approved for acne vulgaris generally, not for a subtype called "hormonal acne." Oral contraceptives are the third piece. The AAD's 2024 guideline, published in the Journal of the American Academy of Dermatology, identifies four combined oral contraceptives FDA-approved for acne in women who also want contraception: norgestimate/ethinyl estradiol, norethindrone acetate/ethinyl estradiol/ferrous fumarate, drospirenone/ethinyl estradiol, and drospirenone/ethinyl estradiol/levomefolate. "The pill clears acne" is label-supported only for those four.
Read the guideline's confidence level, not just its recommendation
A guideline recommendation carries a strength rating, and skipping it is how accurate citations turn into overstated claims. The 2024 AAD guideline rates both spironolactone and combined oral contraceptives as **conditional** recommendations, not strong ones. Conditional means the panel judged the benefits probably outweigh the harms, but the evidence is limited enough that reasonable patients could choose differently.
So a site describing hormonal therapy as the settled first-line treatment for adult female acne overstates what the guideline itself claims. The AAD's own summary of the updated acne guidance is the check: if an article cites AAD support without mentioning that the recommendation is conditional, it has trimmed the part that matters. This cuts both directions. Conditional is not a warning against the drug — it is an instruction to weigh it against alternatives with your prescriber rather than assume it is the default.
The bloodwork question, and how to date a page
One of the clearest tests of whether an acne page is current is what it says about potassium monitoring. Spironolactone can raise potassium, and for years the standard advice was routine blood tests for everyone taking it.
The 2024 AAD guideline changed that: the AAD acne guideline materials state routine potassium monitoring is not needed in otherwise healthy patients, reserving testing for people with risk factors for hyperkalemia. Risk factors that still justify monitoring include: If a page insists every patient needs regular potassium checks and cites no post-2024 source, it is repeating pre-2024 practice. That does not make it dangerous advice — extra testing is cautious, not harmful — but it tells you the page has not been updated, which matters for everything else on it.
- Kidney disease or reduced kidney function
- Heart failure or use of ACE inhibitors, ARBs, or potassium-sparing drugs
- Potassium supplements or high-potassium salt substitutes
- Older age, or any condition your prescriber flags
What the strongest trial actually showed — and why testimonials fail
The best evidence for spironolactone in acne is the SAFA trial, a randomised placebo-controlled study run in England and Wales and published in the BMJ in 2023. As the published trial report records, 81.9% of women taking spironolactone reported improvement at week 24, versus 63.3% on placebo — an odds ratio of 2.72 (95% confidence interval 1.50 to 4.93). Headaches were more common on the drug: 20.4% versus 12.0%. Look hard at the placebo number.
Nearly two-thirds of women taking a dummy pill reported their acne improved over 24 weeks. Acne fluctuates, people change routines, and self-reported improvement drifts upward over time. That is why a before-and-after photo, an influencer's three-month update, or a brand's customer survey proves almost nothing about whether the product did the work. The honest reading is that spironolactone beat placebo by a real and meaningful margin, in one well-run trial, at 24 weeks, in women — with a side effect cost. That is a different claim from "spironolactone clears hormonal acne," and a page that cannot tell the two apart is not a page to make decisions from.
Should you get a hormone panel? The specialties disagree
If a site tells you every adult woman with acne needs a hormone test, it is presenting one side of an unresolved dispute as fact. The AAD advises testing androgens only when another sign of hyperandrogenism is present — hirsutism (coarse hair in a male pattern), irregular periods, rapid-onset severe acne. The Androgen Excess and PCOS Committee took a broader position, recommending total testosterone, free testosterone and DHEAS in all women with adult acne, as documented in this review in the Journal of the Endocrine Society.
Neither position is fringe, and the disagreement is real. What should make you skeptical is a commercial page that resolves the dispute in the direction of the panel it happens to sell, without mentioning the other view exists. A practical middle path: if you have irregular cycles, unusual hair growth, hair thinning, or acne that started suddenly in adulthood, testing is worth raising with a clinician on either standard. If you have none of those, ask what a normal result would change about your treatment before paying for it.
Red flags you can check yourself in two minutes
Two claim patterns are common enough to check on sight. The first is a cosmetic product claiming to treat disease. An FDA analysis of dermatology-related warning letters, published in JAAD, found unapproved-drug claims in 85.5% of 55 cosmetic skin and hair warning letters issued between 2015 and 2020, with misbranding in 63.6%. A cream sold as a cosmetic that says it will "balance your hormones" or "treat acne" is, by that standard, marketing an unapproved drug.
The second is the recycled benzoyl peroxide scare. On 11 March 2025 the FDA reported testing 95 benzoyl peroxide acne products for benzene; the agency's statement says more than 90% had undetectable or extremely low levels, six products were voluntarily recalled at the retail level — La Roche-Posay Effaclar Duo, Walgreens Acne Control Cleanser, two Proactiv products, an SLMD product, and Walgreens Tinted Acne Treatment Cream — and the cancer risk from this exposure is very low. "Benzoyl peroxide was banned" is a misstatement of a limited recall. Before you act on any hormonal acne page, run these four checks: A page that passes all four can still be wrong about you specifically — none of this substitutes for a prescriber who knows your history, your kidney function and your other medications.
- Does it name the FDA approval status, and does it distinguish off-label from approved?
- Does it give the strength of the guideline recommendation, not just its existence?
- Does the evidence it cites have a control group, or is it before-and-after images?
- Does the product's claim match what its regulatory category allows it to say?
Frequently Asked Questions
Is off-label prescribing of spironolactone for acne legal?
Yes. Doctors may prescribe an approved drug for an unapproved use based on clinical judgment. What off-label means practically is that no FDA-reviewed acne dose exists, so dosing comes from clinical practice and trial data rather than a label.
Can men take clascoterone (Winlevi)?
The FDA approval covers acne vulgaris in patients 12 and older in both sexes, per the agency's review of application 213433. Oral anti-androgens like spironolactone are a different situation and are generally prescribed to women.
Should I stop using benzoyl peroxide after the 2025 benzene findings?
FDA's March 2025 testing found over 90% of 95 products had undetectable or extremely low benzene and called the cancer risk very low. Check whether your specific product is among the six recalled; if not, the agency's finding does not support stopping.